单细胞RNA测序表明AP-1是自身免疫性脑膜炎的潜在治疗标
Sichen Zhao1, Dongting Wu1, Yao Lu2
1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou 510060, China.
Biochemical pharmacology
|April 14, 2025
概括
激活蛋白-1 (AP-1) 通过促进致病性T细胞驱动自身免疫性脑膜炎 (AU). 抑制AP-1降低了疾病严重程度和T细胞透,表明AP-1是AU的潜在治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
背景情况:
- 自身免疫性脑膜炎 (AU) 是一种严重的眼睛疾病,其原因复杂,治疗方法有限.
- 了解驱动AU的分子机制对于开发有效疗法至关重要.
研究的目的:
- 通过单细胞RNA测序来研究实验性自身免疫性脑膜炎 (EAU) 的分子驱动因素.
- 通过分析EAU期间的细胞和转录变化来确定AU的新型治疗点.
主要方法:
- 从正常和EAU小鼠的脏和宫排水淋巴结 (CDLNs) 的单细胞RNA测序 (scRNA-seq).
- 在体外研究和采用转移实验以评估激活蛋白-1 (AP-1) 和相关细胞因子的作用.
- 药理上抑制AP-1以评估其在阿联的治疗潜力.
主要成果:
- scRNA-seq揭示了EAU期间细胞组成和基因表达的显著变化.
- AP-1被确定为EAU病变发生的关键分子.
- 抑制AP-1缓解了EAU症状,减少了视网膜和淋巴结中的致病性T细胞 (Th17和Th1) 透,并降低了GM-CSF和IL-23水平.
- 在CD4+T细胞中抑制AP-1抑制了它们诱导EAU的能力.
结论:
- AP-1在EAU病原发生过程中发挥着关键作用,可能是通过GM-CSF/IL-23反循环维持Th17细胞的病原性.
- 抑制AP-1是一种有前途的新疗法策略,用于治疗自身免疫性脑膜炎.
相关概念视频
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
Leaky Scanning
5.0K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.0K


